GSC
TPST icon

Ground Swell Capital’s Tempest Therapeutics TPST Stock Holding History

Ground Swell Capital’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-838
Closed -$15.3K – 256
2024
Q3 		$15.3K Buy
+838
New +$17.2K 0.01% 134

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Ground Swell Capital's TPST Position: Q4 2024 in Review

Ground Swell Capital sold out of Tempest Therapeutics (TPST) in Q4 2024, closing a stake of 838 shares — an estimated $15.3K sold.

Ground Swell Capital first reported a position in TPST in Q3 2024 and held it in 1 quarter. The position peaked at $15.3K in Q3 2024. 33 funds tracked by Wall St. Rank hold TPST as of Q4 2024.

  • Ground Swell Capital reported no remaining Tempest Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Ground Swell Capital sold 838 Tempest Therapeutics shares in Q4 2024, an estimated $15.3K.
  • Ground Swell Capital first reported a position in Tempest Therapeutics in Q3 2024 and held it in 1 quarter.
  • Ground Swell Capital's Tempest Therapeutics position peaked at $15.3K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2024.

Based on Ground Swell Capital's 13F filing for Q4 2024, filed 14 Feb 2025.